Press coverage about Bristol-Myers Squibb (NYSE:BMY) has been trending somewhat positive recently, according to Accern. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Bristol-Myers Squibb earned a news impact score of 0.18 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 47.0047691800093 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:

BMY has been the topic of several research reports. Jefferies Group LLC reaffirmed a “buy” rating and set a $63.00 price objective on shares of Bristol-Myers Squibb in a research report on Wednesday, July 12th. Vetr raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $62.23 price objective on the stock in a research report on Wednesday, July 12th. Deutsche Bank AG set a $55.00 price objective on Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Monday, July 17th. BMO Capital Markets reaffirmed an “underperform” rating and set a $47.00 price objective (down from $51.00) on shares of Bristol-Myers Squibb in a research report on Wednesday, July 26th. Finally, Piper Jaffray Companies set a $60.00 price objective on Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Thursday, July 27th. One analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $64.93.

Bristol-Myers Squibb (BMY) opened at $61.91 on Wednesday. Bristol-Myers Squibb has a 1-year low of $46.01 and a 1-year high of $66.10. The firm has a market cap of $100,951.66, a P/E ratio of 20.84, a P/E/G ratio of 2.43 and a beta of 1.18. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The company had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. Bristol-Myers Squibb’s quarterly revenue was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.77 earnings per share. analysts anticipate that Bristol-Myers Squibb will post 2.99 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th were paid a dividend of $0.39 per share. The ex-dividend date of this dividend was Thursday, October 5th. This represents a $1.56 dividend on an annualized basis and a yield of 2.52%. Bristol-Myers Squibb’s dividend payout ratio is presently 61.42%.

In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the sale, the senior vice president now directly owns 46,297 shares in the company, valued at approximately $2,777,820. The sale was disclosed in a document filed with the SEC, which is available through this link. 0.23% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/08/bristol-myers-squibb-bmy-getting-somewhat-positive-press-coverage-report-finds.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Insider Buying and Selling by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.